Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
Clinical trial NCT02083484 · NO_LONGER_AVAILABLE
Trial details
- NCT number
- NCT02083484
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- NO_LONGER_AVAILABLE
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.